[
    [
        {
            "time": "2023-11-02",
            "original_text": "长春高新业绩会：生长激素集采价格尚未确定，地产业务占用资金不会超过100亿 资金问题",
            "features": {
                "keywords": [
                    "长春高新",
                    "生长激素",
                    "集采价格",
                    "地产业务",
                    "资金"
                ],
                "sentiment_score": -0.2,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "房地产"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "长春高新业绩会：生长激素集采价格尚未确定，地产业务占用资金不会超过100亿 资金问题",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-11-02",
            "original_text": "长春高新：在生长激素领域，金赛药业拥有“纯化的PEG化人生长激素缀合物及其药物制剂”的发明专利和“含PEG化人生长激素缀合物的药物及其应用”等发明专利",
            "features": {
                "keywords": [
                    "长春高新",
                    "生长激素",
                    "金赛药业",
                    "发明专利",
                    "技术优势"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "长春高新：在生长激素领域，金赛药业拥有“纯化的PEG化人生长激素缀合物及其药物制剂”的发明专利和“含PEG化人生长激素缀合物的药物及其应用”等发明专利",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-11-02",
            "original_text": "长春高新：从容投资、德邦证券等31家机构于11月2日调研我司",
            "features": {
                "keywords": [
                    "长春高新",
                    "机构调研",
                    "从容投资",
                    "德邦证券"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "长春高新：从容投资、德邦证券等31家机构于11月2日调研我司",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]